A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara et al. · The Lancet Oncology · 2008 · 1.9K citations

Surgical Oncology, Spirits Trial, Gastrointestinal Oncology +8

Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma

Michael I. D’Angelica, Mithat Gönen, Murray F. Brennan et al. · Annals of Surgery · 2004 · 615 citations · Full text

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients

Yuh Sakata, Atsushi Ohtsu, N Horikoshi et al. · European Journal of Cancer · 1998 · 564 citations

Medicinal Chemistry, Oncology, Gastrointestinal Oncology +9

Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

Wasaburo Koizumi, Minoru Kurihara, Shuji Nakano et al. · Oncology · 2000 · 440 citations

Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer

Kazuhiro Yoshida, Motoki Ninomiya, Norihisa Takakura et al. · Clinical Cancer Research · 2006 · 172 citations